📰 Alvr News
Alvr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alvr. Real-time updates on events, politics, business and more.
February 22, 2024
AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) has been assigned a consensus rating of “Reduce” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The […]
January 28, 2024
Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) have received an average recommendation of “Reduce” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the […]
January 26, 2024
Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) have earned a consensus rating of “Reduce” from the six analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the […]
January 16, 2024
AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 7,700,000 shares, a drop of 32.0% from the December 15th total of 11,320,000 shares. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is […]
January 5, 2024
AlloVir Inc. a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff,...
January 4, 2024
By Ben Glickman AlloVir will cut about 95% of its current employee base after scrapping three late-stage clinical trials. The cell-therapy developer said in...
December 29, 2023
Bank of America cut shares of AlloVir (NASDAQ:ALVR – Free Report) from a buy rating to an underperform rating in a report published on Tuesday morning, Marketbeat reports. Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. cut shares of AlloVir from an overweight rating to an underweight […]
December 26, 2023
SVB Leerink downgraded shares of AlloVir (NASDAQ:ALVR – Free Report) from an outperform rating to a market perform rating in a report published on Friday, MarketBeat reports. ALVR has been the topic of several other research reports. Piper Sandler downgraded shares of AlloVir from an overweight rating to a neutral rating in a research note […]
December 25, 2023
SVB Leerink lowered shares of AlloVir (NASDAQ:ALVR – Free Report) from an outperform rating to a market perform rating in a report published on Friday, MarketBeat reports. A number of other analysts have also recently commented on the stock. Piper Sandler cut shares of AlloVir from an overweight rating to a neutral rating in a […]
December 25, 2023
Piper Sandler lowered shares of AlloVir (NASDAQ:ALVR – Free Report) from an overweight rating to a neutral rating in a report issued on Friday, MarketBeat reports. Separately, JPMorgan Chase & Co. lowered AlloVir from an overweight rating to an underweight rating in a report on Friday. One investment analyst has rated the stock with a […]